Table 1. Characteristics of lung cancer GWASs of the International Lung Cancer Consortium (ILCCO).
| Study | Cases | Controls | Location | Study design | Illumina genotyping platform | Number of SNPs |
|---|---|---|---|---|---|---|
| Scanning phase | ||||||
| MDACCa | 1 150 | 1 134 | Texas, USA | Hospital-based case–control | 317K | 312 829 |
| TORONTOb | 331 | 499 | Toronto, CA | Hospital-based case–control | 317K | 314 285 |
| CE (IARCc) | 1 854 | 2 453 | Romania, Hungary, Slovakia, Poland, Russia, Czech Republic | Multicenter hospital-based case–control | 317K, 370Duo | |
| GLCd | 487 | 480 | Germany | Population-based case–control (<50 years) | HumanHap550K | 503 381 |
| Replication phase | ||||||
| DeCODE Genetics | 830 | 11 228 | Iceland | Population-based case–control | 317K, 370Duo | 290 386 |
| HARVARD | 984 | 970 | Massachusetts, USA | Hospital-based case–control | 610Quad | 543 697 |
| NCI GWAS | 506 062 | |||||
| EAGLEe | 1 920 | 1 979 | Italy | Population-based case–control | HumanHap550v3_B, 610Quad | |
| ATBCf | 1 732 | 1 271 | Finland | Cohort | HumanHap550K, HumanHap610 | |
| PLCOg | 1 380 | 1 817 | 10 US Centers | Cohort-Cancer Prevention Trial | 317K / 240S, HumanHap550v3_B, HumanHap610 | |
| CPS-IIh | 697 | 674 | all US states | Cohort | HumanHap550K, 610Quad | |
| Overall | 11 365 | 22 505 | ||||
a MD Anderson Cancer Center.
b Toronto study by Lunenfeld-Tanenbaum Research Institute.
c Central Europe Study of the International Agency for Research on Cancer.
d German Lung Cancer Study.
e Environment And Genetics in Lung cancer Etiology study.
f Alpha-Tocopherol, Beta-Carotene Cancer Prevention study.
g Prostate, Lung, Colon, Ovary screening trial.
h Cancer Prevention Study II nutrition cohort.